Go Pro
→ China Declares War (From Porter & Company) (Ad)tc pixel Free BPTSY Stock Alerts

Biophytis (BPTSY) Competitors

$0.25 0.00 (0.00%)
As of 08/20/2026
Compare

BPTSY vs. SXTC, CANF, CMND, CDT, and BPTH

Should you buy Biophytis stock or one of its competitors? Biophytis's main competitors and comparable companies include China SXT Pharmaceuticals (SXTC), Can-Fite BioPharma (CANF), Clearmind Medicine (CMND), CDT Equity (CDT), and Bio-Path (BPTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Biophytis compare to China SXT Pharmaceuticals?

Biophytis (NASDAQ:BPTSY) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Biophytis has a beta of 2.46, suggesting that its share price is 146% more volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

China SXT Pharmaceuticals has higher revenue and earnings than Biophytis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A-$18.43MN/AN/A
China SXT Pharmaceuticals$1.14M1.73-$6.20MN/AN/A

In the previous week, China SXT Pharmaceuticals had 3 more articles in the media than Biophytis. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 0 mentions for Biophytis. Biophytis' average media sentiment score of 0.00 equaled China SXT Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Biophytis Neutral
China SXT Pharmaceuticals Neutral

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 3.7% of Biophytis shares are owned by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
BiophytisN/A N/A N/A
China SXT Pharmaceuticals N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biophytis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

China SXT Pharmaceuticals beats Biophytis on 6 of the 7 factors compared between the two stocks.

How does Biophytis compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Can-Fite BioPharma has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, meaning that its stock price is 146% more volatile than the broader market.

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Can-Fite BioPharmaN/A N/A N/A
Biophytis N/A N/A N/A

Can-Fite BioPharma has higher revenue and earnings than Biophytis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can-Fite BioPharma$405K5.39-$7.63M-$22.80N/A
BiophytisN/AN/A-$18.43MN/AN/A

In the previous week, Can-Fite BioPharma had 1 more articles in the media than Biophytis. MarketBeat recorded 1 mentions for Can-Fite BioPharma and 0 mentions for Biophytis. Can-Fite BioPharma's average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company Overall Sentiment
Can-Fite BioPharma Neutral
Biophytis Neutral

Can-Fite BioPharma currently has a consensus target price of $44.00, indicating a potential upside of 1,221.32%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Can-Fite BioPharma is more favorable than Biophytis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Biophytis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Can-Fite BioPharma beats Biophytis on 7 of the 9 factors compared between the two stocks.

How does Biophytis compare to Clearmind Medicine?

Biophytis (NASDAQ:BPTSY) and Clearmind Medicine (NASDAQ:CMND) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Biophytis' return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
BiophytisN/A N/A N/A
Clearmind Medicine N/A -143.79%-88.51%

0.1% of Biophytis shares are held by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are held by institutional investors. 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A-$18.43MN/AN/A
Clearmind MedicineN/AN/A-$3.86M-$139.98N/A

In the previous week, Biophytis' average media sentiment score of 0.00 equaled Clearmind Medicine'saverage media sentiment score.

Company Overall Sentiment
Biophytis Neutral
Clearmind Medicine Neutral

Biophytis has a beta of 2.46, suggesting that its stock price is 146% more volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

Summary

Biophytis beats Clearmind Medicine on 4 of the 6 factors compared between the two stocks.

How does Biophytis compare to CDT Equity?

Biophytis (NASDAQ:BPTSY) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biophytis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CDT Equity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Biophytis' average media sentiment score of 0.00 equaled CDT Equity'saverage media sentiment score.

Company Overall Sentiment
Biophytis Neutral
CDT Equity Neutral

0.1% of Biophytis shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 3.7% of Biophytis shares are held by company insiders. Comparatively, 7.3% of CDT Equity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A-$18.43MN/AN/A
CDT EquityN/AN/A-$39.22M-$3.35 thousandN/A

Biophytis has a beta of 2.46, indicating that its share price is 146% more volatile than the broader market. Comparatively, CDT Equity has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

Biophytis' return on equity of 0.00% beat CDT Equity's return on equity.

Company Net Margins Return on Equity Return on Assets
BiophytisN/A N/A N/A
CDT Equity N/A -72.25%-55.44%

Summary

Biophytis beats CDT Equity on 4 of the 7 factors compared between the two stocks.

How does Biophytis compare to Bio-Path?

Bio-Path (NASDAQ:BPTH) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Bio-Path has a beta of -0.51, suggesting that its share price is 151% less volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, suggesting that its share price is 146% more volatile than the broader market.

Biophytis' return on equity of 0.00% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
Biophytis N/A N/A N/A

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 3.7% of Biophytis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company Overall Sentiment
Bio-Path Neutral
Biophytis Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08M-$1.09N/A
BiophytisN/AN/A-$18.43MN/AN/A

Summary

Biophytis beats Bio-Path on 4 of the 6 factors compared between the two stocks.

Get Biophytis News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPTSY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPTSY vs. The Competition

Export
MetricBiophytisPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$586K$12.45B$7.27B$12.76B
Dividend YieldN/A2.64%2.54%11.09%
P/E RatioN/A784.87270.6924.20
Price / SalesN/A761.74639.89109.39
Price / CashN/A92.1276.8953.23
Price / Book-0.0211.8513.436.37
Net Income-$18.43M$2.80B$3.46B$347.74M
7 Day PerformanceN/A1.92%2.15%0.06%
1 Month PerformanceN/A3.70%6.18%2.86%
1 Year PerformanceN/A6.59%24.96%17.13%

Biophytis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPTSY
Biophytis
N/A$0.25
flat		N/AN/A$586KN/AN/A30
SXTC
China SXT Pharmaceuticals
0.2467 of 5 stars		$4.80
-6.4%		N/A-100.0%$2.29M$1.14MN/A90
CANF
Can-Fite BioPharma
1.4716 of 5 stars		$3.41
-1.3%		$44.00
+1,191.8%		-75.0%$2.25M$405KN/A8
CMND
Clearmind Medicine
1.5696 of 5 stars		$1.92
-2.0%		N/A-99.6%$1.95MN/AN/AN/A
CDT
CDT Equity
0.7469 of 5 stars		$3.01
+4.2%		N/A-99.9%$1.90MN/AN/A3

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BPTSY) was last updated on 8/22/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Your Free Report (Inside)
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
23,281 stocks. Only ONE survived.
One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...
Monument Traders Alliance | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
The world's #2 gold miner is running on fumes [it has to buy]
Barrick, the world's second-largest gold miner, produced 7.77 million ounces in 2010. This year, output is exp...
Golden Portfolio | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel